ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Scientist II, Immunoassay Development at Vaxcyte - ApplyBlast

Associate Scientist II, Immunoassay Development

Vaxcyte

24 days ago

3.9 on Glassdoor

San Carlos, California, United States

Onsite

Full Time

Medior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Vaxcyte is seeking an Associate Scientist II to join the CMC Immunoassay group, providing scientific and strategic leadership for the development and lifecycle management of critical reagents and reference materials. This role supports the vaccine pipeline by executing immunoassays, assisting with method development, and ensuring high-quality laboratory documentation and data integrity. The position involves close collaboration with scientists and laboratory leaders to advance analytical testing needs across the company's vaccine programs.

Responsibilities

Execute immunoassays for potency, antigenicity, and characterization testing
Develop and qualify critical reagents and reference materials
Support method development and troubleshooting studies

Skills

Qualifications

BS in BiochemistryBS in ImmunologyBS in Analytical ChemistryBS in Biological SciencesM.S. in a related discipline

About Vaxcyte

vaxcyte.com

Headquarters

San Carlos, California, United States

Company Size

51-200 employees

Founded

2013

View Profile

Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections — including invasive pneumococcal disease, Group A Strep, and Shigella — using advanced chemistry and a proprietary cell-free protein synthesis platform. Its lead programs, VAX-31 (a 31-valent PCV) and VAX-24 (a 24-valent PCV), are being evaluated in Phase 3 trials for the prevention of invasive pneumococcal disease, with additional early-stage candidates targeting Group A Strep and Shigella. Vaxcyte is also investing up to $1 billion in U.S. biomanufacturing expansion to support scalable vaccine production.